Classification of Parkinson's Disease Gait Using Spatial-Temporal Gait Features

2015 ◽  
Vol 19 (6) ◽  
pp. 1794-1802 ◽  
Author(s):  
Ferdous Wahid ◽  
Rezaul K. Begg ◽  
Chris J. Hass ◽  
Saman Halgamuge ◽  
David C. Ackland
Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 112
Author(s):  
Seung Hyun Lee ◽  
Sang-Min Park ◽  
Sang Seok Yeo ◽  
Ojin Kwon ◽  
Mi-Kyung Lee ◽  
...  

The second most common progressive neurodegenerative disorder, Parkinson’s disease (PD), is characterized by a broad spectrum of symptoms that are associated with its progression. Several studies have attempted to classify PD according to its clinical manifestations and establish objective biomarkers for early diagnosis and for predicting the prognosis of the disease. Recent comprehensive research on the classification of PD using clinical phenotypes has included factors such as dominance, severity, and prognosis of motor and non-motor symptoms and biomarkers. Additionally, neuroimaging studies have attempted to reveal the pathological substrate for motor symptoms. Genetic and transcriptomic studies have contributed to our understanding of the underlying molecular pathogenic mechanisms and provided a basis for classifying PD. Moreover, an understanding of the heterogeneity of clinical manifestations in PD is required for a personalized medicine approach. Herein, we discuss the possible subtypes of PD based on clinical features, neuroimaging, and biomarkers for developing personalized medicine for PD. In addition, we conduct a preliminary clustering using gait features for subtyping PD. We believe that subtyping may facilitate the development of therapeutic strategies for PD.


2020 ◽  
Vol 13 (5) ◽  
pp. 508-523 ◽  
Author(s):  
Guan‐Hua Huang ◽  
Chih‐Hsuan Lin ◽  
Yu‐Ren Cai ◽  
Tai‐Been Chen ◽  
Shih‐Yen Hsu ◽  
...  

2021 ◽  
Author(s):  
Nikhil J. Dhinagar ◽  
Sophia I. Thomopoulos ◽  
Conor Owens-Walton ◽  
Dimitris Stripelis ◽  
Jose Luis Ambite ◽  
...  

2018 ◽  
Author(s):  
Wei Yi ◽  
Emma J. MacDougall ◽  
Matthew Y. Tang ◽  
Andrea I. Krahn ◽  
Ziv Gan-Or ◽  
...  

AbstractMutations in Parkin (PARK2), which encodes an E3 ubiquitin ligase implicated in mitophagy, are the most common cause of early onset Parkinson’s Disease (PD). Hundreds of naturally occurring Parkin variants have been reported, both in PD patient and population databases. However, the effects of the majority of these variants on the function of Parkin and in PD pathogenesis remains unknown. Here we develop a framework for classification of the pathogenicity of Parkin variants based on the integration of clinical and functional evidence – including measures of mitophagy and protein stability, and predictive structural modeling – and assess 51 naturally occurring Parkin variants accordingly. Surprisingly, only a minority of Parkin variants, even among those previously associated with PD, disrupted Parkin function. Moreover, a few of these naturally occurring Parkin variants actually enhanced mitophagy. Interestingly, impaired mitophagy in several of the most common pathogenic Parkin variants could be rescued both by naturally-occurring (p.V224A) and structure-guided designer (p.W403A; p.F146A) hyperactive Parkin variants. Together, the findings provide a coherent framework to classify Parkin variants based on pathogenicity and suggest that several pathogenic Parkin variants represent promising targets to stratify patients for genotype-specific drug design.


2018 ◽  
Vol 22 (6) ◽  
pp. 1765-1774 ◽  
Author(s):  
Carlotta Caramia ◽  
Diego Torricelli ◽  
Maurizio Schmid ◽  
Adriana Munoz-Gonzalez ◽  
Jose Gonzalez-Vargas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document